Revenue → Gross profit: $15.5BPharmaceutical → Revenue: $14.6BMedical devices → Revenue: $7.9BRevenue → Cost of revenue: $7.0BGross profit → SG&A: $5.5BOncology → Pharmaceutical: $5.4BGross profit → R&D: $5.0BImmunology → Pharmaceutical: $4.6BGross profit → Operating profit: $3.2BOperating profit → Net profit: $2.7BSurgery → Medical devices: $2.4BOrthopaedics → Medical devices: $2.2BInterventional → Medical devices: $2.0BGross profit → Other expense: $1.8BNeuroscience → Pharmaceutical: $1.8BVision → Medical devices: $1.3BPulmonary → Pharmaceutical: $1.1BOther pharma → Pharmaceutical: $0.9BInfectious diseases → Pharmaceutical: $0.8BOperating profit → Tax: $0.6BInterest → Operating profit: $0.1BGross profit → Restructuring: $0.0BCost of revenue$7.0B5% Y/YGross profit$15.5B5% Y/YImmunology$4.6B-5% Y/YInfectious diseases$0.8B-3% Y/YInterest$0.1B-46% Y/YInterventional$2.0B26% Y/YMedical devices$7.9B6% Y/YNet profit$2.7B-37% Y/YNeuroscience$1.8B1% Y/YOncology$5.4B19% Y/YOperating profit$3.3B-36% Y/YOrthopaedics$2.2B1% Y/YOther expense$1.8B260% Y/YOther pharma$0.9B-8% Y/YPharmaceutical$14.6B5% Y/YPulmonary$1.1B16% Y/YR&D$5.0B44% Y/YRestructuring$41M-74% Y/YRevenue$22.5B5% Y/YSG&A$5.5B1% Y/YSurgery$2.4B-2% Y/YTax$0.6B-29% Y/YVision$1.3B3% Y/YJohnson & Johnson Q3 FY24 Income Statementcreated with SankeyArt.com
2022
Q4 Full Year
2023
Q1 Q2 Q3 Q4 Full Year
2024
Q1 Q2 Q3